For more information call (888) LUHS-888.
Ellen R. Gaynor
Adults = 18 years of age must have been diagnosed with a solid tumor or hematologic malignancy and must not be likely to undergo hematopoietic cell transplant. Participants must either be: 18 years of age or older and receiving a cytotoxic or immunosuppressive chemotherapy regimen that does not include rituximab or 50 years of age or older with a hematologic malignancy not in remission, regardless of whether the patient is or is not receiving chemotherapy and are not expected to require rituximab therapy beginning three months prior to enrollment through 28 days post vaccination dose 4. The life expectancy must be = 12 months, and participants must be able to understand and complete study questionnaires. Participants must have a history of varicella, antibodies to VZV or residence in a country with endemic VZV infection, or if participants are
The purpose of this study is to test the safety, tolerability and effectiveness of the vaccine, V212, on participants with cancer.